Reyataz - Bristol-myers | Article One Partners
One moment please.

You are using unknown unknown. Some features may not be supported and the experience may be degraded using an older browser.

industry icon Reyataz - Bristol-myers

These patents cover the drug REYATAZ. It is used to treat HIV, which causes acquired immunodeficiency syndrome (AIDS).

Description

The active ingredient of REYATAZ is atazanavir sulfate.

The patents relate to the structure, compositions, formulations and methods of use of atazanavir sulfate.
Name of Substance
Atazanavir
Atazanavir [INN:BAN]
BMS 232632

Synonyms
ATV
ATZ
Atazanavir
CGP 73547
HSDB 7339
Latazanavir
UNII-QZU4H47A3S
Zrivada

Systematic Name
2,5,6,10,13-Pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-, dimethyl ester,
(3S,8S,9S,12S)-2,5,6,10,13-Pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-, dimethyl ester, (3S-(3R*,8R*,9R*,12R*))-

In allowing the claims of the ‘911 patent, the examiner wrote:
“Claims 1-11 are allowed. The closest prior art is Fassler et al. (J. Med. Chem. 1996, vol. 39, pages 3203-3216) disclose aza-peptide analogs as potent Human Immunodeficiency Virus Type-1 Protease Inhibitors with oral bioavailability.
The instant claims differ from the reference in having the substituted phenyl group at R4 position, whereas the reference teach [sic] unsubstituted phenyl group at the same position. This difference was neither taught or suggested by the prior art of record.” 

Research Requirements:

Latest Date for Responses
1995-04-21
Relevant Patent Dates
US Patent Date
Priority Date
US Application Date
Priority Date
EP Date
Publication Date
Other Patent Authorities
Publication Date

See the claims in the downloadable copies of the patents.

Study Guidelines:

All submissions must be made by 12 Noon ET on the Study Close Date. You may submit up to the submission limit indicated on your Activity Dashboard. Your submission limit for the Study may be increased based on the quality of your previous submissions for the same Study.

Highlights: When prompted by the submission form, you must highlight the most important parts of your submission in the fields provided. The submission may not be eligible for Rewards if the citations or highlights are incomplete or insufficient.

Translations: A non-English submission must include an English translation of at least the highlighted section. If the reference appears to be relevant, a Reviewer may contact you for an extended translation.

CS Experts: All Experts assigned to this CrowdSearch Study must submit the Expert Questionnaire twice. The first Questionnaire is due on Day 10 of the Study, and the second Questionnaire is due during Week 5 or at the completion of the Study. If the Questionnaires are not submitted, the Expert may risk losing the Reward. Study participants not assigned as Experts are not asked to submit the Questionnaire.

The Researcher Agreement and all other eligibility requirements apply. Submissions may not be shared with other Researchers.

Please refer to our FAQ portal if you have any general questions.  Feel free to contact AOP Support at support@articleonepartners.zendesk.com if you need further information. AOP Support is available Monday-Friday between 9 AM - 5 PM ET. Please allow up to 48 hours for a response as we gather the most accurate information to address your query.